The Economic Times
English Edition
| E-Paper
Search
+

    Aurobindo Pharma shares gain 0.33% as Sensex rises

    Synopsis

    A total of 107,940 shares changed hands on the counter till 12:41PM (IST)

    Getty Images
    As long as Nifty does not close above 11,720, it can slip towards 11,600.
    Shares of the Ltd. traded at Rs 977.35 on BSE at 12:41PM (IST) on Wednesday, up 0.33 per cent. The stock quoted a 52-week low price of Rs 737.9 and a high of Rs 1063.75.

    Earlier in the day, the stock saw a gap up opening.

    At the prevailing price, the stock traded at 10.72 times its trailing 12-month EPS of Rs 91.05 per share and 1.44 times its book value, as per BSE data.

    Did you Know?

    Stock score of Aurobindo Pharma Ltd moved down by 2 in a week.

    View Latest Stock Report  »

    A total of 107,940 shares changed hands on the counter till 12:41PM (IST). The stock commands a market value of Rs 57208.12 crore and is part of the Pharma - Indian industry.

    The scrip has been an underperformer , up 25.95 per cent in the past one year in comparison with a 63.66 per cent gain in Sensex.

    During the day, the stock moved between Rs 981.85 and Rs 969.65.

    Promoter/FII Holding
    Promoters held 48.86 per cent in the company as of 31-Mar-2021. FII and MF ownership in Aurobindo Pharma Ltd. stood at 24.37 per cent and 8.84 per cent, respectively.
    (What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    New on
    Get In-depth Reports on 4,000+ Stocks, updated daily
    Make Investment decisions
    Make Investment decisions
    with proprietary stock scores on earnings, fundamentals, relative valuation, risk and price momentum
    Find new Trading ideas
    Find new Trading ideas
    with weekly updated scores and analysts forecasts on key data points
    In-Depth analysis
    In-Depth analysis
    of company and its peers through independent research, ratings, and market data
    Read before you invest. Insights on Aurobindo Pharma Ltd.. Explore Now
    The Economic Times

    Stories you might be interested in